Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
16
ANAB Quote, Financials, Valuation and Earnings
Last price:
$14.55
Seasonality move
:
-2.76%
Day range:
$14.20 - $15.29
52-week range:
$14.20 - $41.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.95x
P/B ratio:
5.23x
Volume:
1.6M
Avg. volume:
686.3K
1-year change:
-25.68%
Market cap:
$441.2M
Revenue:
$17.2M
EPS (TTM):
-$6.08
Analysts' Opinion
-
Consensus RatingAnaptysBio has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.70, AnaptysBio has an estimated upside of 146.21% from its current price of $14.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing -24.14% downside risk from its current price of $14.50.
Fair Value
-
According to the consensus of 9 analysts, AnaptysBio has 146.21% upside to fair value with a price target of $35.70 per share.
ANAB vs. S&P 500
-
Over the past 5 trading days, AnaptysBio has underperformed the S&P 500 by -5.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AnaptysBio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AnaptysBio has grown year-over-year revenues for 8 quarters straight. In the most recent quarter AnaptysBio reported revenues of $30M.
Earnings Growth
-
AnaptysBio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AnaptysBio reported earnings per share of -$1.14.
Enterprise value:
11.1M
EV / Invested capital:
0.13x
Price / LTM sales:
6.95x
EV / EBIT:
--
EV / Revenue:
0.19x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
-0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-36.55%
Net Income Margin (TTM):
-289.75%
Return On Equity:
-236.31%
Return On Invested Capital:
-236.31%
Operating Margin:
-75.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $4.5M | $15M | $57.2M | $3.3M | $30M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$120.3M | -$148.2M | -$140.1M | -$37.7M | -$22.8M | |
| EBITDA | -$114.4M | -$128M | -$125.6M | -$32.3M | -$16.8M | |
| Diluted EPS | -$4.82 | -$5.42 | -$6.08 | -$1.41 | -$1.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $345.8M | $386.6M | $450.4M | $428M | $448.7M | |
| Total Assets | $384.8M | $424.3M | $618.5M | $487.3M | $493.4M | |
| Current Liabilities | $24.5M | $20.9M | $21.1M | $39.2M | $43.9M | |
| Total Liabilities | $24.5M | $40.7M | $340.9M | $366.9M | $409.1M | |
| Total Equity | $360.2M | $383.6M | $277.6M | $120.4M | $84.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$88.2M | -$97.1M | -$103M | -$36.5M | -$10.1M | |
| Cash From Investing | -$483M | $117.1M | $174M | $30.6M | $58.6M | |
| Cash From Financing | $293.4M | -$52.2M | $94.3M | -$3.1M | $71.2M | |
| Free Cash Flow | -$88.4M | -$97.8M | -$103.4M | -$36.6M | -$10.1M | |
ANAB
Sector
Market Cap
$441.2M
$44.6M
Price % of 52-Week High
35.1%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-9.86%
-0.68%
1-Year Price Total Return
-25.68%
-29.09%
Beta (5-Year)
-0.111
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$15.45
200-day SMA
Sell
Level
$27.31
Bollinger Bands (100)
Sell
Level
22.27 - 36.89
Chaikin Money Flow
Buy
Level
104.5K
20-day SMA
Sell
Level
$20.51
Relative Strength Index (RSI14)
Sell
Level
30.89
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-97.3898
50-day SMA
Sell
Level
$23.97
MACD (12, 26)
Sell
Level
-2.57
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-5.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.006)
Sell
CA Score
(Annual)
Level (-2.4706)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.1046)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Stock Forecast FAQ
In the current month, ANAB has received 6 Buy ratings 3 Hold ratings, and 0 Sell ratings. The ANAB average analyst price target in the past 3 months is $35.70.
-
Where Will AnaptysBio Stock Be In 1 Year?
According to analysts, the consensus estimate is that AnaptysBio share price will rise to $35.70 per share over the next 12 months.
-
What Do Analysts Say About AnaptysBio?
Analysts are divided on their view about AnaptysBio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AnaptysBio is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is AnaptysBio's Price Target?
The price target for AnaptysBio over the next 1-year time period is forecast to be $35.70 according to 9 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ANAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AnaptysBio is a Buy. 6 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANAB?
You can purchase shares of AnaptysBio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AnaptysBio shares.
-
What Is The AnaptysBio Share Price Today?
AnaptysBio was last trading at $14.55 per share. This represents the most recent stock quote for AnaptysBio. Yesterday, AnaptysBio closed at $14.50 per share.
-
How To Buy AnaptysBio Stock Online?
In order to purchase AnaptysBio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
